We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Urinary Cytokine Levels as a Prognostic Marker for Kidney Scarring After Pyelonephritis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2009 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00868270
First Posted: March 24, 2009
Last Update Posted: March 24, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hillel Yaffe Medical Center
  Purpose
The prevalence of kidney scarring after UTI is approximately 5-57%. UTIs are caused mainly by bacteria that cause local and systemic immunological reaction that are accompanied by cytokines. These cytokines are a main factor in the inflammatory process. They are produced by leukocytes, macrophages, fibroblasts, endothelial cells and epithelial cells in the kidney tissue. Interleukin 6 and 8 (IL-6 IL-8) were found in high levels in the urine of children and adults who suffer from UTIs. Other studies on animals have found a relationship between inflammatory reaction and scarring in the kidney. We hypothesize that we will find a similar relationship between the level of IL-6, IL-8 in the urine during acute pyelonephritis in children and the probability of kidney scarring.

Condition
Kidney Scarring Post-Febrile UTI

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • High prevalence of kidney scarring in children with high levels of urine interleukins [ Time Frame: six months ]

Estimated Enrollment: 35
Study Start Date: May 2009
Groups/Cohorts
Children with UTIs

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 7 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hospitalized children with UTIs
Criteria

Inclusion Criteria:

  • Children aged 0-7
  • First episode febrile UTI

Exclusion Criteria:

  • Recurrent UTI
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00868270


Contacts
Contact: Hassan Jassar, MD 972-4-630-4332 hasjassar@hotmail.com

Locations
Israel
Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: Hassan Jassar, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

Responsible Party: Hassan Jassar, MD, Pediatrics Dept. Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT00868270     History of Changes
Other Study ID Numbers: HY55-08
First Submitted: March 22, 2009
First Posted: March 24, 2009
Last Update Posted: March 24, 2009
Last Verified: March 2009

Additional relevant MeSH terms:
Cicatrix
Fibrosis
Pathologic Processes